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Tt present study was performed to examine whether
residues 36-62 of TNFcx contain the chemotactic domain
ofTNF, and whether the p55 and p75 TNF receptors are
involved in TNFcz induced chemotaxis. The chemotactic
effect of TNFcz on PMN was inhibited by the mAbs Hrt-Tb
and Utr-1, against thep andpT TNF receptors, respec-
tively. Both receptors may therefore be required for me-
diating the chemotactic effect of TNFcz. The synthetic
TNFcx 36-62, similar to TNFcx, had chemotactic effects on
bothPMN and monocytes. The chemotactic activity ofthe
TNFcz 36-62 peptide on PMN, was inhibited by Htr-Tb,
Utr-I and soluble p5 receptor, which shows that the
peptide possessed the ability to induce chemotaxis
through the TNF receptors. In contrast to TNFcx, the
peptide did not show a cytotoxic activity against WEHI
164 flbrosarcoma cells. It is suggested that different do-
mains of the TNFcx molecule induce distinct biological
effects.
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Circulating polymorphonuclear cells (PMN) and
monocytes are activated by chemotactic factors for
recruitment to sites of inflammation. The pleiotropic
cytokine, tumour necrosis factor- (TNF), has been
reported to be chemotactic, as it induces directional
locomotion of PMN and monocytes in vitro. ’-5 Fur-
thermore, in vivo studies show that TNF0t plays a
crucial role in the recruitment of neutrophils at an
early stage, and monocytes at a later stage of immune
complex-induced inflammatory reactions.6,7 Many
biological effects induced by TNF:-11 have been
shown to involve binding to the 55 kDa (p55) and
the 75 kDa (p75) TNF receptors, which are expressed
on almost all cell types,m However, the involvement
of these receptors in the TNFx induced chemotaxis
has not been studied.
An interesting approach for the study of distinct
TNF{x activities is the use ofTNF peptides. Different
TNF peptides have recently been reported to in-
duce distinctTNF effects, 2-14 and inhibit binding of
TNF to the TNF receptors. The authors have per-
formed molecular dynamic calculations15 combined
with studies on the three-dimensional structure of
TNF0t16 in order to design TNF0t peptides which
could interact with TNF receptors, and induce TNF0t
effects. It was found that a peptide including residues
36-62 had conformational properties which could be
related to the corresponding parent molecule. This
sequence is also one of the most homologous do-
mains between TNF and TNF, which both bind to
the TNF receptors.e In the present study, this peptide
was investigated for two crucial TNF0t effects,
chemotaxis and cytotoxicity. The involvement of p55
an p75 TNF receptors in the chemotactic response of
TNF and TNF{x 36-62, was also studied.
Materials and Methods
Molecular modelling: The molecular modelling stud-
ies of TNF peptides were performed using the
Molecular Simulation Inc. Quanta 3.2/CHARMm 21.2
program package, on a Silicon Graphics Personal IRIS
4D/30 EG (USA). The peptide atom coordinates were
obtained from the TNF0t X-ray structure (pdbl tnf),
and peptide candidates were minimized by molecu-
lar mechanics using 2000 steps of adopted basis set
Newton-Raphson minimization, before the mini-
mized structures were subjected to molecular dy-
namic calculations with a total simulation of 250 ps
at 300 K.
Synthesis ofTNFpeptides: TNF: peptides were syn-
thesized as described previously,
7 using Fmoc chem-
istry on a semi-automatic peptide synthesizer
(Milligen, Model 9020). The peptides were purified
and analysed using reverse-phase HPLC, and FIB-MS
on a VG Tribid MS instrument (VG Analytical, Man-
chester, UK).
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Materials: Human recombinant TNF0t (Hr TNF00,
with a specific activity of 1.0 x 108 U/mg, was pur-
chased from Boeringer (Mannheim, Germany). The
generation of the mAbs Utr-1 an Htr-7b, specific for
p75 and p55 respectively, is described elsewhere, TM
and soluble p55 was kindly provided by Dr
Hansruedi Loetscher, Hoffman-La Roche (Basel,
Switzerland). Anti-IL-8 and anti-MCP-1 were pur-
chased from British Biotechnology (UK).
Formylmethionyl-leucyl phenylalanine (FMLP) was
purchased from Sigma Chemical Co. (St Louis, MO).
Endospecy from Seikagaku Co. (Tokyo, Japan) was
used to check endotoxin contamination.
PMN isolation: Polymorphonuclear cells (PMN) were
isolated as follows: 2 ml of freshly drawn
heparinized blood (10 U/ml) from healthy adults
was applied on top of a bilayer consisting of 3 ml
polymorphoprep and 3 ml lymphoprep in
polycarbonate tubes (Nycomed Pharma AS, Nor-
way). After centrifugation at 530 xg for 20 min, the
PMN band in the polymorphoprep layer was iso-
lated. The cells were washed once with ice cold
sterile 0.15 M NaCl, and centrifuged at 185 xg for
10 min. Contaminating erythrocytes in the PMN band
were lysed with ice cold 0.2% NaCl for 90 s. The cells
were resuspended at 106/ml in ice cold RPMI-1640
and used immediately. The PMN preparation con-
tained at least 95% neutrophils.
Monocyte isolation: The monocyte band was isolated
using the method previously described by Byum. 19
In brief, mononuclear cells (PMBC) from healthy
adults, from either freshly drawn heparinized blood
or buffy coats (10 U/ml), were centrifuged on
lymphoprep, isolated and washed with 0.15 M NaCl.
The PMBC, resuspended at 106/ml in RPMI-1640
were used directly for chemotaxis studies.
Assayfor chemotaxis: TNF andTNF peptides were
tested for chemotactic activity on PMN and PBMC.
Chemotactic activity was assayed in a 48-well micro-
chemotaxis chamber (Neuro Probe Inc. Cabin John,
MD, USA), as described previously,
i In brief, the
upper wells were filled with 50 l-tl of cells, and 25 l.tl
of the compounds tested for chemotaxis were filled
in the bottom wells. For checkerboard analysis, the
stimulants were also placed in the upper wells. In the
pretreatment studies, the anti-TNF receptor antibod-
ies, or other antibodies were added to the cells for
10min at 4C, before they were placed in the
upper wells. The soluble p55 was mixed with
0.5 l.tM TNF0t 36-62 in a 1:1 molar ratio at 20C for
10min, before addition to the lower wells. A
polycarbonate-polyvinyl pyrrolidone (PVP) filter
with 51.tm pore size was used in the PBMC
chemotaxis assay, while a PVP-free polycarbonate
filter, with the same pore size, was used for the PMN
chemotaxis assay. Chemotaxis chamber assemblies
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were incubated at 37C in humidified 95% air and 5%
CO2 for 3 h in assays with PBMC and 40 min in assays
with PMN. Then the filters were removed, fixed in
2.5% glutaraldehyde (Merck, Damstad, Germany),
and stained with Giemsa (Sigma, Cleveland, USA) for
30 min. Cells that had migrated through to the bot-
tom of the filter were counted in 6-10 high-power
fields (HPF) (x 60 or 100 objective). Chemotactic
bioactivity was expressed as the mean number of
cells per HPF. Variations in response to the tested
agents, were dependent on the blood donor.
Assay for cytotoxicity: Cytotoxicity of TNF 36-62
was tested using the fibrosarcoma cell line WEHI 164
clone 13, as described by Espevik et al.
21 Cell viability
in the assay was measured colorimetrically, by using
tetrazolium salt (MTT), as described by Mosmann et
al. 22
Results
Molecular modelling ofTNFe 36-62peptide: Starting
from a minimized X-ray structure, the conformational
properties ofTNF 36-62 in a vacuum environment
were calculated using molecular dynamics. The re-
suits from the calculations suggested that the peptide
would possess a partially conserved tertiary structure
similar to the conformation in the minimized crystal
structure of TNF (Fig. 1). Parts of [-strands from
each of the two [-sheets in the TNF0t monomer are
included in TNF0t 36-62 (Figs. 1A and 1B). The
strands in TNF0t 36-62 were stabilized by hydrogen
bonds, but some of these were different from the
corresponding hydrogen bonds observed in the
TNF{x structure. A -strand interruption in TNF0t
could also be recognized in the peptide. The two
loops (38-41 and 50-54) located at the base of TNF{x,
and important residues surrounding a shallow de-
pression which are suggested to be involved in
receptor binding,6 were all exposed in a similar
manner in the peptide as in TNFx. The distance
between the carbon in the C-terminal carboxyl and
the nitrogen in the N-terminal amino group in TNF0t
36-62 was only 2.89 A compared to 18.19 A in TNF,
indicating an attraction between the oppositely
charged C- and N-terminals. The effect of this elec-
trostatic attraction is, however, expected to be of
much less importance in aqueous environment.
Chemotactic effects ofTNFo and TNF 36-62peptide
on PMN: TNF and the TNF0t 36-62 peptide have
been tested for the ability to attract PMN. The experi-
ments were repeated at least three times, and similar
results were obtained despite donor variations. Both
TNF0t and TNF 36-62 showed a dose dependent
chemotactic effect on PMN. Migration of approxi-
mately 120 cells was achieved with either 2 nMTNF
or 10 l.tM TNF0t 36-62 (Fig. 2). That a higher concen-p55 andp75 mediate chemotaxis induced by TNF 36-62
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FIG. 1. Drawing of the TNFa monomer and the TNFa 36-62 peptide. (A) Drawing of the a-carbon backbone of the minimized crystal structure of TNFa.
The sequence consisting of residues 36-62 are blackened. (B) Drawing of the a-carbon backbone of the TNFa sequence 36-62. (C) Drawing of the
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FIG. 2. Dose dependent effect of TNFa and TNFa 36-62 on PMN migra-
tion. Indicated concentrations of TNFa (,), and TNFa 36-62 (=1) were
tested for chemotactic effect on PMN with RPMI (F"I) as a control. Migrated
cells were counted in high-power fields (HPF) (x 60 objective). Results are
presented as means + S.E.M. (n 9).
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The indicated concentrations of TNF 36-62 peptide or medium
alone were added to the upper compartments of the chemotaxis
chamber, to neutralize the chemotactic effect of TNF( 36-62 used
in the lower compartments. Migrated PMN were counted in high-
power fields (HPF) (x 60 objective). The data represent the
mean + S.E.M. (n= 9). *The number of migrating PMN with the
peptide present at the same concentration in both compartments.
tration of TNF0t 36-62 was needed to induce migra-
tion of the same number of cells as induced byTNF,
is probably due to lack of domains necessary for
optimal binding of T.NF0t 36--62.12 FMLP was used as
a positive control at 10-7 M, and gave an l 1-fold
migration of PMN compared to the negative control
RPMI. As for TNF, a Zigmond-Hirsch checkerboard
analysis confirmed that TNF0t 36-62 displayed
chemotactic, and not chemokinetic effects on PMN
(Table 1). A different TNFot peptide including
residues 78-96, used at the same concentrations as
TNF 36-62, did not exhibit any chemotactic effect
on PMN. We also tested whether TNF{x and TNF
36-62 had chemotactic effects on PBMC, and ob-
served that both stimulants induced chemotatic ac-
tivities on PBMC in a dose dependent manner and at
similar concentrations as for PMN (data not shown).
Both stimulants with their buffers were tested and
confirmed free of LPS using the Endospecy assay.
Inhibition of TNF and TNF{x 36-62-induced
chemotaxis on PMN: Both mAb, Utr-1 and Htr-7b,
specific for p75 and p55 respectively, significantly
inhibited the chemotactic response ofTNF on PMN
(Fig. 3A), when used separately or in combination.
Likewise, the chemotactic effect of TNF0t 362
peptide was also significantly inhibited by Utr-1 or
Htr-7b (Fig. 3B) or a combination of both mAb.
These mAb alone, or in combination, did not induce
chemotaxis on PMN. FMLP induced migration was
not inhibited by these mAb alone or in combination.
The experiments were repeated four times, and simi-
lar results were obtained despite donor variations.
Antibodies against IL-8 or MCP-1 did not show any
inhibitory effect on either the TNF, TNF 36-62 or
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FIG. 3. Inhibitory effect of anti-p55 and anti-p75 antibodies on the chemotactic effect on PMN, induced by TNF and TNF 36-62. Utr-
1(10 mg/ml) and Htr-7b(10 mg/ml) (anti-p75 and anti-p55, respectively) were preincubated with cells for 10 min at 4C. the PMN were then
tested for chemotaxis toward (A) 0.6 nM TNF and (B) 10 IM TNF 36-62 with () or without () antibodies (I-l:control). Migrated cells
were counted in high-power fields (HPF) (x 100 objective). The data represent the mean _
S.E.M. (n 8). "p< 0.001 compared to TNF or
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FIG. 4. Inhibitory effect of the soluble p55 receptor on PMN chemotaxis
induced byTNF 36-62. TNFe 36-62 or FMLP were tested for their ability
to induce migration of PMN with () or without () soluble p55 ([]: control).
Soluble p55 was preincubated with TNF 36-62 or FMLP for 10 min at
20C. Migrated cells were counted in high-power fields (HPF) (xl00 objec-
tive). The results are expressed as mean + S.E.M. (n 6). "p < 0.001 com-
pared with TNF 36-62 alone. N.S. not significant.
FMLP induced chemotaxis on PMN when used in the
same concentrations as Utr-1 and Htr-7b.
TNFot 36-62 interacted with solublep55: The soluble
p55 was able to significantly inhibit the chemotactic
response of the TNF0t 36-62 peptide on PMN (Fig. 4).
Soluble p55 did not inhibit the chemotactic effect of
FMLP (Fig. 4), indicating a specific binding of TNF0t
36-62.
TNF{x 36-62 had no cytotoxic effect: TNF0 36-62 was
tested for cytotoxic activity. In contrast to TNF0t,
TNF 36-62 did not show any cytotoxic effect on the
WEHI 164 clone 13 fibrosarcoma cell line, when
tested up to a 104-fold higher concentration than
TNF.
Discussion
In the present study it is shown that both TNF0t
36-62 andTNF is a chemoattractant to PMN in vitro.
It is also shown that the chemotaxis induced by
TNF0t and TNF0t 36-62 is mediated through both
p55 and p75 TNF receptors. The finding regarding
TNF0t as a chemoattractant is in line with previous
reports showing that antibodies against TNF
inhibit TNFc induced chemotaxis in vitro on PMN
and monocytes, respectively. It is noticeable
that there have been conflicting reports about
the chemotactic property of TNF(x. 2-5,23,24 In the
authors’ opinion the discrepancy might be explained
by variations in experimental conditions, donor
variations and sensitivities of the test systems. TNF
has also been shown to stimulate production of
the chemoattractant IL-8 by granulocytes and
monocytes. 25 Since interleukin-8 (IL-8) shows
chemotactic activity for PMN,2,26 TNFc might induce
release of IL-8 by PMN, which in turn could be
responsible for the chemotactic effect observed in
our experiment. However, the present work shows
that anti-IL-8 and anti-MCP-1 antibodies did not in-
hibit the chemotactic response of TNF0t. This ex-
cludes IL-8 and MCP-1 as responsible for the
chemotactic activity observed.
It is shown that the chemotactic activity TNF on
PMN involves both p55 and p75 receptors. Even non-
redundancy in the function of the two receptors for
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some effects has been observed, 27 a simultaneous
involvement of both p55 and p75 receptors has been
reported for a series of TNF0t activities, such as
induction of differentiation of ML-1 cells, NF-cB
activation, cytotoxicity on U937 cells and IL-6 pro-
duction by endothelial cells. 27-29 Tartaglia et al.3 have
suggested that the high affinity p75 receptor may
regulate the rate of TNF0t association with the p55
receptor, by increasing the local concentration of
TNF0t through rapid ligand association and dissocia-
tion. In contrast to this, Brouckaert et al.1 have
proposed an alternative cooperation between the
two receptors where p75 interferes with the p55
signalling pathway. This hypothesis is based on the
fact that p75 triggering is not sufficient to initiate
the redundant signals and that p75 triggering can
diminish p55 mediated c-fos induction. However, it
remains to be explored how the two receptors
cooperate in TNF0t induced chemotaxis.
Similar to TNF0t, the TNF0t 36-62 peptide also
induced chemotaxis on PMN and PBMC. The finding
that soluble p55 inhibited this effect (Fig. 3), indi-
cates that the peptide possesses the conformation
needed for interaction with the receptor. This sup-
ports the results of the molecular dynamic calcula-
tions (Fig. 1). That TNF{x 36-62 is able to interact with
soluble p55, is also in line with the recent work by
Ratjen et al.1 who found that several bioactive TNFx
peptides were able to inhibit binding ofTNF to the
TNF receptors. Antibodies against p55 and p75 inhib-
ited TNF0t 36-62 induced chemotaxis on PMN, which
indicates that this peptide, like TNF, induces the
chemotactic activity through both TNF receptors. It is
noticeable that Postlewaite et al.’ have observed
chemotaxis on fibroblasts, by using another TNF
peptide, which also included the sequence 36-62.
Although these authors did not show that the
chemotaxis induced by the peptide was TNF receptor
mediated, desensitisation studies suggested involve-
ment of TNF receptors. The present work supports
and extends this hypothesis.
TNF0 36-62 was not cytotoxic, suggesting the
existence of distinct TNFc regions for the cytotoxic
and chemotactic effects. It is noteworthy that two
other TNF peptides, which overlap with only four
residues (54-58), were shown to be cytotoxic,1 sug-
gesting a critical domain for TNF cytotoxicity. This
sequence is included in ourTNF 36-62 peptide and
the molecular calculations of the peptide suggested
that this specific domain encompassing residues
54-58 did not possess the conformation needed for
optimal interaction with the TNF receptors. This was
due to the attraction between the oppositely charged
C- and N-terminals (Fig. 1).
Crystallographic studies on the TNF[3/TNF receptor
complex have shown that three TNF]3 monomers
bind three TNF receptors in a symmetrical fashion.2
It has been suggested that a crosslinking of TNF
receptor is also necessary for signal transduction
leading to TNFo effects,3-5 and is based, on studies
with antibodies and TNFot mutants against TNF
receptors.3-6 Our and other investigations with syn-
thetic TNFot peptide fragments, 1’-14 however, suggest
that at least some of the TNFc effects are not depend-
ent on crossreaction of TNF receptors with three
TNFot monomers.
In conclusion, different TNFot peptides may induce
distinct activities, indicating that TNF possess dis-
tinct domains critical for different TNF activities.
This property opens the possibility of designing
TNFx fragments with specific TNFot effects. We are
currently investigating this hypothesis by studying
TNFot 36-62 and several other TNF peptides for their
bioactivities and specificities to target cells.
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